YZ-0252

YZ-0252 is a small molecule inhibitor of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway, currently in preclinical development by Guangdong Yinzhu Pharmaceutical Technology. The drug is being developed for the treatment of solid tumors, with a specific focus on its potential to enhance the efficacy of PD-1 antibodies through combination therapy. NF-κB plays a critical role in regulating genes involved in inflammation, cell proliferation, and apoptosis; in the context of oncology, its inhibition is intended to suppress tumor growth and modulate the immune microenvironment to overcome resistance to checkpoint inhibitors.